Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides mostly transcribed by RNA which do not encode proteins. Previously, lncRNAs were considered transcriptional byproducts called "junk DNA" with no biological functions. There are many studies conducted on lncRNAs showing they are actively involved in regulation of epigenetic, transcriptional, and post-transcriptional events. Expressions of lncRNAs are more different in many malignant tumors than in benign tumors and normal tissue. Aberration of lncRNAs is responsible to promote or suppress tumorigenesis and cancer progression. Under different circumstances, lncRNAs exhibit their roles in carcinogenesis such as MALAT1 is responsible for intervening mRNA instability, HOTAIR, MALAT1, ANRIL, PVT1 links with miRNA and histonemodifying complexes, MEG3 associates with miRNA, CCAT2, MEG3, GAS5, UCA1 allies with c-Myc or P53 causing suppression of tumor or oncogenesis. Abnormal expressions of lncRNAs are noticed in gynecological cancers, such as cervical cancer, ovarian cancer, and endometrial cancer. Identification of cervical cancer associated lncRNAs is necessary to understand the molecular biogenesis of cancers. In this review, we summarized the foundation and function of the lncRNAs in terms of tumor progression, invasion, prognosis, apoptosis, metastasis, and chemo-resistance. This review will provide references to determine the clinical applications of lncRNAs as ideal diagnostic biomarkers or therapeutic targets in cervical cancers.
Introduction
Cervical cancer is the second most common cancer and fourth leading cause of mortality in women worldwide [1] . Although the incidence has declined in the developed countries in the past 20 years, it still has a high mortality rate in developing countries. There is high incidence seen in low resource countries, especially in Africa, Latin America, parts of Asia and in some eastern European countries with incidences rising up to 100/100,000. In contrast, the incidence may be as low as 10/100,000 women in developed countries [2] . The lower incidence of cervical cancer in industrialized countries is consequential of awareness and screening programs that were introduced in these countries over several decades ago. Cervical cancer screening then became the prototype of cancer prevention programme by early detection of preneoplastic lesions. Carcinoma in situ is most commonly seen in women aged 35 -39 years likewise the cervical cancer incidence is high in women aged 30 -34 years (17/1,000,000). Almost all invasive cervical carcinomas undergo a stage of the intraepithelial stage, and morphological alterations of early stages of cervical cancer are detectable. According to the epithelial involvement, cervical squamous intraepithelial neoplasia (CIN) is classified into CIN1, CIN2, and CIN3. The transformation from dysplasia to invasive cervical cancer is a very slow progressing process. The development of CIN1 to CIN3 is 10% and CIN1 to invasive carcinoma is 1% whereas the rate of progression of CIN2 to CIN3 and cervical cancer are 20% and 5% respectively, and CIN3 to invasive cancer is greater than 12% [3] [4] [5] .
To comprehend the molecular pathogenesis of cervical cancer, it is important to understand the HPV infection. Human papillomavirus (HPV) is a doublestranded DNA virus from the papillomavirus family. It is known to be a leading cause of cervical cancer and its precursor lesions. There are 6 early genes (E1, E2, E4, E5, E6, E7) and 2 late genes (L1, L2) in HPV DNA. The early genes regulate the viral replications and the interaction with the host cells. The late genes encrypt for the capsid proteins. Among them, E6 and E7 are known as oncoproteins. Once the virus enters the host cells, E6 and E7 integrate the host DNA and encode for oncoproteins. Subsequently, E6 oncoproteins bind with the host p53 tumor suppressor gene and result in its inactivation. E7 binds to the tumor suppressor gene pRb, p21, p27 and results in cellular transformation. Till date, more than 200 subtypes of HPV have been identified. It has been categorized into two subtypes: High risk and low-risk types [6] [7] . Persistent infection with high-risk genotypes of the human papillomavirus (hrHPV) has been documented as the principal cause of cervical cancer. 90% of HPV infection will be eliminated by the host immune system and only minority of women will turn out to develop pre-invasive cancer [8] . Much evidence has shown that human papillomavirus 16 and 18, the hrHPV subtypes are the most common cause of almost 70% of all cervical cancers [9] .
There are about more than 3000 long non-coding RNAs labeled in humans. 
HOTAIR
HOX transcript antisense intergenic RNA (HOTAIR) is 2.2 kb long and has 6 exons. It is located at the antisense strand of the HOXC gene cluster in chromosome 12q13.13. It was first identified from HOXC gene cluster for its involvement in the determining the proximal-distal axis during development [39] [40] [41] . HOTAIR interacts with PRC2 to target the HOXD locus, resulting in H3K27-trimethylation and gene silencing by histone methyltransferase EZH2, signifies that HOTAIR selectively targets PRC2 complex to silence the transcription of HOXD locus [39] . VEGF and MMP-9 play a crucial role in developing a tumor by increasing cell migration and invasion. In cervical cancer expression of HOTAIR is associated with VEGF and MMP-9 explaining the high expression of HOTAIR upregulates VEGF and MMP-9 resulting in progression of cervical cancer. HOTAIR also has a role play in recurrence of cervical cancer. Low expression of HOTAIR inhibits cellular proliferation, migration, and invasion of cervical cancer. EmT is also important in cell migration and invasion. EMT-related genes in cervical cancer were reversed with the inhibition of HOTAIR [17] [42].
ANRIL
Antisense Non-coding RNA in the INK4 Locus (ANRIL) is a newly discovered lncRNA. It is 3.8 kb in length. It is located in the 9p21 chromosomal region. It is transcribed in the opposite direction from its neighboring INK4B/ARF-INK4A Open Journal of Obstetrics and Gynecology gene cluster. ANRIL was first identified in a genetic analysis of melanoma with neural tumors [18] . ANRIL is intensely associated with a genetic marker of coronary artery disease and also upregulated in prostate cancer [18] . The loci where ANRIL is located is highly susceptible to cardiovascular disease [43] ANRIL epigenetically inhibits tumor suppressors CDKN2A (p16) and CDKN2B (p15), and in doing so it plays a substantial role in cellular proliferation and senescence [51] [52] [53] . Tumor suppressors CDKN2A (p16), ARF (p14) and CDKN2B (p15) have a major participation in cell proliferation, apoptosis, and senescence. ANRIL is involved in suppression of p16 (INK4A), p14 (ARF), p15 (INK4B). ANRIL is interrelated with the advancement of cell cycle progression and suppression of apoptosis and senescence. Depletion of tumor suppressor INK4B (p15) and upregulation of the anti-apoptotic Bcl-2 explains ANRIL enhances cell proliferation [54] . Low expression of ANRIL upregulates tumor suppressors p15 levels but shows no influence in the expression of p16 or p14 causing cell-cycle arrest at the G2/M phase, facilitating growth suppression [55] . A recent study exhibits that expression of pro-oncogenic protein Ras stimulates the expression of p15INK4B and p16INK4A ensuing inhibition on ANRIL expression [53] . ANRIL overexpression is directly associated with the advanced FIGO 
MEG3
Maternally expressed gene (MEG3) lncRNA is 1.6 kb in length consisting of 10 exons, belonging to DLK1-MEG3 locus imprinted in human chromosome 14q32. [62] . Downregulation of MEG3 strongly correlates with advanced with advanced FIGO stage, enlarged tumor size, depth of tumor, metastasis to lymph nodes and presence of hrHPV [25] . Cervical cancer tissues markedly expressed lower levels of MEG3 compared to the adjacent normal tissue. Likewise over expression of MEG3 exhibit strikingly suppression in growth and increased apoptosis by p53 and caspase which convinced it as a tumor suppressor [63] [64] . Therefore these findings determine MEG3 is one of the lncRNAs with tumor suppressor activity.
GAS5
Growth arrest-specific transcript 5 (GAS5) lncRNA has many small nucleolar RNAs (snoRNAs), microRNAs (miRNAs) and PIWI-interacting RNAs (piRNAs) located in the 1q25 chromosomal region which was initially extracted from mouse NIH 3T3 cells using subtraction hybridization [35] [65] . There are many pieces of evidence showing that downregulation of GAS5 acts as a tumor suppressor in various types of cancers in humans, such as breast cancer, prostate cancer, and lung cancer [66] [67] [68] . Cyclin-dependent kinase 6 (CDK6) is a GAS-5 associated protein which enhances cell cycle progression in bladder cancer. The decrease in the expression of GAS-5 considerably increased CDK6 expressions reducing G0/G1 phase significantly and escalating S phase confirms GAS-5 regulates CDK6 [69] . Due to its tumor suppressive character GAS5 is considered as a rising star among all the lncRNAs. When GAS5 expression was decreased interestingly there was an increase in the expression of miR-21. GAS5 induced apoptosis and significantly suppressed cell growth, tumor invasion, and lymph node metastasis in cervical cancer [36] . Signaling pathway P13K/Akt is an important regulator for promoting cellular proliferation, cellular growth and survival. Some study reports P13K/Akt has a significant part in cisplatin-resistance cancer cells [70] . Downregulation of GAS5 increased expression of miR-21 causing decreases in PTEN, it's one of the genes in the PI3K/Akt pathway activating the PI3K/Akt pathway. Therefore, low expression of GAS5 increases the expression of miR-21which is responsible for regulation of PTEN explaining the cisplatin resistance in cervical cancer cells [71] . Therefore this evidence confirms GAS5 is an independent marker for predicting the clinical outcome in cervical cancer.
CCAT2
Colon cancer-associated transcript 2 (CCAT2) is 0.4 kb long lncRNA located in the 8q24.21 chromosomal region. It was first discovered in colorectal cancer in 2013 [28] . Many studies are evident that CCAT2 promotes chromosomal instability, cellular progression and tumor metastasis in various kinds of cancer such as colon [28] , lung cancer [72] breast cancer [73] , gastric cancer [74] , ovary can-Open Journal of Obstetrics and Gynecology cer [75] and cervical cancer [30] . Knockdown of CCAT2 inhibited the cell development, growth and promoted cell death [29] . CCAT2 upregulates MYCregulated miRNA-17-5p and miRNA-20a responsible for cellular proliferation, chromosomal modifications, and metastasis in many cancers via [76] . Dysregulation activation of the Wnt/β-catenin signaling pathway contributes the development of human cancers [77] . Transcription factor 7-like 2(TCF7L2) is known to be an inducer of Wnt/β-catenin signaling pathway. CCAT2 binds with TCF7L2, upregulates MYC, miR-17-5p, and miR20a expressions triggering Wnt signaling pathway [78] . The upregulation of CCAT2 positively influences the Wnt/β-catenin signaling pathway to promote proliferation and metastasis of cancer cells [79] . The expression of CCAT2 was relatively high in cervical cancer tissues than normal tissues. [30] . CCAT2 expression was highly dependent on cervical invasion depth, FIGO stage, and lymph node metastasis. The correlation between CCAT2 and metastasis reveals a poor prognosis in cervical cancer [80] .
Therefore, overexpression of CCAT2 was theorized as an independent prognostic factor for poor overall survival in cervical cancer. Additionally, knockdown of CCAT2 by transfection of siRNA induced G 0 /G 1 phase cell cycle arrest and apoptosis [81] .
UCA1
Urothelial cancer associated 1(UCA1) is 2.3 kb long located in 19p13.12 encodes 3 isoforms (1.4, 2.2 and 2.7 kb) and expresses 2 transcripts. The isoform 2.2 kb in length has been identified as drug-resistant (CUDR) [22] [82] Since CUDR is not so easily detected in normal tissues and due to its relatively low expression than other biomarkers of cancer, it can be an effective biomarker to identify the development of cancer and its therapeutic responses [83] . In 2006 UCA1 was initially identified in human bladder transitional cell carcinoma with high specificity and sensitivity [82] [84] . Growing evidences have reported that UCA1 is abundant in various kinds of cancers, including bladder cancer, colorectal cancer, esophageal squamous cell carcinoma, tongue squamous cell carcinoma, breast cancer, gastric cancer, ovarian cancer, cervical cancer and melanoma [23] [84]- [90] . Aberrant expressions of UCA1 in cervical cancer suggests that it encourages cisplatin resistance in cervical cancer cells through signaling pathways regulating cell apoptosis, which are involved in balancing expression of caspase-3, p21, CDK2, and survivin. Increased level of survivin and decreased the level of p21 boosted cellular proliferation and also downregulating caspase 3 and up-regulating CDK2 suppressed apoptosis representing UCA1 has crucial regulatory mechanisms in the cisplatin-resistance in cervical cancer cells [91] . Thus the provided evidence supports that UCA1 can be used as an effective biomarker for therapeutic strategy and to identify the development of cervical cancer.
PVT1
Plasmacytoma variant translocation 1(PVT1) is a >300 kb long intergenic Open Journal of Obstetrics and Gynecology lncRNA located in the 8q24 chromosomal region of the human genome which is also the commonest sites of cancer-related amplifications containing both MYC and PVT1 [92] [93] . PVT1 involvement in carcinogenesis was first demonstrated by frequent translocations in mouse plasmacytomas and Burkitt's lymphomas in human [94] [95] [96] . Many reports have shown significant overexpression of PVT1 in relation with risk, recurrence, and survival in many cancers [26] [93] [97]- [102] . PVT1 has gained attraction from the cancer field due to its frequent co-amplification with MYC in several solid tumors. Assembled evidence reported that more than 45% of 500 ovarian cancers have co-amplification with tion, cell cycle progression, and migration of cervical cancer cells [105] . As a result, knockdown of PVT1 in cervical cancer cells decreased proliferation, migration and invasion and increased apoptosis and cisplatin cytotoxicity, suggesting that PVT1 functions as a multidimensional role in cervical carcinogenesis [106] .
In a cohort study, the PVT1 level was measured in cervical cancer, cervical intraepithelial neoplasia (CIN) and normal cells; the result showed that serum PVT1 is high in cervical cancer and distinctly distinguishes cervical cancer suggesting PVT1 may be a novel noninvasive diagnostic biomarker for cervical cancer [27] .
CCHE1
Cervical carcinoma high-expressed 1 (CCHE1) lncRNA is 2500 nucleotides long and is located on chromosome 10. Upregulation of CCHE1 is significantly correlated with advanced FIGO stages, increased tumor size, invasion, and prognosis in cervical cancer. CCHE1 binds to physically associates with proliferating cell nuclear antigen (PCNA)mRNA, promoting its expressions and consequently increasing proliferation of cervical cancer cells. In contrast, depletion of PCNA stamp out the effects of CCHE1 on the proliferation of cervical cancer cells thus indicating that CCHE1 could be a prognostic factor and therapeutic target for cervical cancer [31] .
HULC
Highly up-regulated in liver cancer (HULC) is a recently found lncRNA 0.5 kb in length encoded in chromosome 6p24.3. HULC was found originally in hepatocellular carcinoma and is also highly expressed in various tumors, such as he- 
Conclusion
Aberrant expressions of lncRNAs have been noted in many types of cervical cancer. Identification of cervical cancer associated lncRNAs is important for understanding the molecular biogenesis of cervical cancer. Studies on the association of lncRNAs in cervical cancer are still in its preliminary stages. Accumulating evidence postulates that dysregulated expressions of lncRNAs have been linked to clinicopathological features in cervical cancer. However, not so much is known about the impact of lncRNAs expressions on cell proliferation, metastasis, and apoptosis in cervical cancer. Evidence regarding the long non-coding RNA expression in cervical cancer reveals that the configuration of lncRNA expression in the cervical cancer cell and precancerous lesions provides important information about its role in cancer initiation, tumor progression, and metastatic spread. There is a large scale of studies investigating the long non-coding RNA expressions in different kinds of cancer. Expression pattern of many lncRNAs needs to be mapped and be further studied to understand its functions and expressions in cervical cancer. The lncRNAs mentioned in this review have several strong evidences providing the needed information to justify its expressions in cervical cancer. The detailed understanding of its mechanism and functions may lead to the identification of new liabilities in cervical cancer. The identification of lncRNA involved in carcinogenesis, tumor suppression, or metastasis provides new prospects to develop novel therapeutics of cancer by targeting those lncRNAs. Drug-resistance is a major challenge that confines the efficacy of treatment in cancer. lncRNAs conferring the drug-resistance phenotype are appreciated for its outcome. DNA repair and cell cycle progression, sensitivity to apoptotic-effect, the involvement of lncRNA in modulating signaling pathways, drug transporter expression and elimination are recognized as resistance therapeutic measures. A massive number of studies have been seeking for novel diagnostic biomarkers for cervical cancer; lncRNAs have shown its potentials as independent biomarkers for early diagnosis and prognostic factor. In the future lncRNAs might serve as early diagnostic biomarkers and novel targets for early prophylaxis and effective treatment and gene therapy of cervical cancer. The use of lncRNAs as biomarkers has prompted considerable interest in researchers and it can be expected that in the upcoming years, some lncRNAs might become useful biomarkers for prognosis and effective treatment to cervical cancer.
